Coherus Oncology (CHRS) Competitors $1.18 +0.06 (+4.87%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. ATYR, SLDB, AUTL, PRME, ERAS, ETON, CGEM, TNXP, ITOS, and GOSSShould you be buying Coherus Oncology stock or one of its competitors? The main competitors of Coherus Oncology include aTyr Pharma (ATYR), Solid Biosciences (SLDB), Autolus Therapeutics (AUTL), Prime Medicine (PRME), Erasca (ERAS), Eton Pharmaceuticals (ETON), Cullinan Therapeutics (CGEM), Tonix Pharmaceuticals (TNXP), iTeos Therapeutics (ITOS), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Coherus Oncology vs. Its Competitors aTyr Pharma Solid Biosciences Autolus Therapeutics Prime Medicine Erasca Eton Pharmaceuticals Cullinan Therapeutics Tonix Pharmaceuticals iTeos Therapeutics Gossamer Bio aTyr Pharma (NASDAQ:ATYR) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Is ATYR or CHRS more profitable? Coherus Oncology has a net margin of 125.90% compared to aTyr Pharma's net margin of 0.00%. Coherus Oncology's return on equity of 0.00% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets aTyr PharmaN/A -93.69% -68.83% Coherus Oncology 125.90%N/A -34.85% Do analysts recommend ATYR or CHRS? aTyr Pharma presently has a consensus target price of $21.25, suggesting a potential upside of 298.31%. Coherus Oncology has a consensus target price of $4.68, suggesting a potential upside of 295.22%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe aTyr Pharma is more favorable than Coherus Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals and insiders hold more shares of ATYR or CHRS? 61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 3.7% of aTyr Pharma shares are held by company insiders. Comparatively, 8.1% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, ATYR or CHRS? Coherus Oncology has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioaTyr Pharma$230K2,272.94-$64.02M-$0.80-6.67Coherus Oncology$266.96M0.52$28.51M$1.550.76 Which has more risk & volatility, ATYR or CHRS? aTyr Pharma has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Does the media refer more to ATYR or CHRS? In the previous week, aTyr Pharma had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for aTyr Pharma and 0 mentions for Coherus Oncology. aTyr Pharma's average media sentiment score of 0.32 beat Coherus Oncology's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the media. Company Overall Sentiment aTyr Pharma Neutral Coherus Oncology Neutral SummaryCoherus Oncology beats aTyr Pharma on 9 of the 17 factors compared between the two stocks. Get Coherus Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$137.73M$3.10B$5.82B$9.71BDividend YieldN/A2.23%3.84%4.09%P/E Ratio0.7621.0530.9025.97Price / Sales0.52400.98469.81120.77Price / Cash3.6743.0937.1558.38Price / Book1.158.089.116.37Net Income$28.51M-$54.72M$3.26B$265.56M7 Day Performance12.86%2.17%1.85%1.71%1 Month Performance28.48%7.13%4.86%1.05%1 Year Performance-10.23%12.70%31.15%20.94% Coherus Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus Oncology3.9559 of 5 stars$1.19+4.9%$4.68+295.2%-15.7%$137.73M$266.96M0.76330ATYRaTyr Pharma2.0992 of 5 stars$4.91+0.2%$21.25+332.8%+163.3%$480.14M$230K-6.1453News CoverageShort Interest ↑Gap UpSLDBSolid Biosciences3.526 of 5 stars$6.03-1.3%$15.00+148.8%-43.1%$475.78M$8.09M-2.15100AUTLAutolus Therapeutics3.0787 of 5 stars$1.88+5.6%$9.12+385.1%-57.1%$473.73M$10.12M-2.24330PRMEPrime Medicine2.8974 of 5 stars$3.50-2.0%$8.92+154.8%-26.8%$471.01M$4.96M-1.71234Gap UpERASErasca1.9961 of 5 stars$1.53-6.7%$4.29+180.1%-47.2%$465.22MN/A-3.40120ETONEton Pharmaceuticals2.4084 of 5 stars$16.37-3.9%$29.67+81.2%+312.8%$456.97M$39.01M-102.3120Positive NewsInsider TradeCGEMCullinan Therapeutics1.7642 of 5 stars$7.95+3.8%$28.60+259.7%-57.4%$452.51MN/A-2.4630News CoverageAnalyst ForecastAnalyst RevisionTNXPTonix Pharmaceuticals3.1318 of 5 stars$40.07-22.0%$70.00+74.7%-0.4%$450.13M$10.09M-1.0250Gap UpHigh Trading VolumeITOSiTeos Therapeutics2.3791 of 5 stars$10.11flat$15.50+53.3%-41.7%$446.92M$35M-2.1690Positive NewsGOSSGossamer Bio3.289 of 5 stars$1.99+1.5%$8.50+327.1%+130.9%$445.67M$114.70M-3.21180 Related Companies and Tools Related Companies aTyr Pharma Alternatives Solid Biosciences Alternatives Autolus Therapeutics Alternatives Prime Medicine Alternatives Erasca Alternatives Eton Pharmaceuticals Alternatives Cullinan Therapeutics Alternatives Tonix Pharmaceuticals Alternatives iTeos Therapeutics Alternatives Gossamer Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access